{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:04:11Z","timestamp":1789207451542,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE-1223785"],"award-info":[{"award-number":["CHE-1223785"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000088","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19GM106990"],"award-info":[{"award-number":["U19GM106990"]}],"id":[{"id":"10.13039\/501100000088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005637","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000088","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.coph.2014.02.006","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T19:12:43Z","timestamp":1395515563000},"page":"24-30","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development"],"prefix":"10.1016","volume":"16","author":[{"given":"Andrew C","family":"Kruse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Kobilka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2014.02.006_bib0005","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","article-title":"Chapter 36. Pulmonary Pharmacology","author":"Barnes","year":"2011"},{"key":"10.1016\/j.coph.2014.02.006_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","article-title":"Muscarinic receptor antagonists: effects on pulmonary function","volume":"208","author":"Buels","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.coph.2014.02.006_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2014.02.006_bib0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0163-7258(03)00004-4","article-title":"Muscarinic acetylcholine receptors and airway diseases","volume":"98","author":"Coulson","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.coph.2014.02.006_bib0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2014.02.006_bib0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1096\/fj.03-0648fje","article-title":"Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors","volume":"18","author":"Fisher","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2014.02.006_bib0035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/mol.64.6.1444","article-title":"Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice","volume":"64","author":"Struckmann","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coph.2014.02.006_sbref0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10753","article-title":"Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist","volume":"482","author":"Haga","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_sbref0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_sbref0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_bib0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11208620-000000000-00000","article-title":"Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2014.02.006_bib0060","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2014.02.006_bib0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.109.163188","article-title":"The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics","volume":"333","author":"Casarosa","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2014.02.006_bib0070","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1021\/jm401219y","article-title":"Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor","volume":"56","author":"Tautermann","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2014.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1039\/c002938f","article-title":"Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders","volume":"6","author":"Digby","year":"2010","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.coph.2014.02.006_bib0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/med.20166","article-title":"Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities","volume":"30","author":"De Amici","year":"2010","journal-title":"Med Res Rev"},{"key":"10.1016\/j.coph.2014.02.006_bib0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2010.07.010","article-title":"Allosteric modulation of G protein-coupled receptors: a pharmacological perspective","volume":"60","author":"Keov","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2014.02.006_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","article-title":"Bridging the gap: bitopic ligands of G-protein-coupled receptors","volume":"34","author":"Lane","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2014.02.006_bib0095","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/j.ddtec.2012.12.003","article-title":"Dualsteric GPCR targeting and functional selectivity: the paradigmatic M2 muscarinic acetylcholine receptor","volume":"10","author":"Bock","year":"2013","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.coph.2014.02.006_bib0100","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.tetlet.2010.04.130","article-title":"Convergent, short synthesis of the muscarinic superagonist iperoxo","volume":"51","author":"Kloeckner","year":"2010","journal-title":"Tetrahedr Lett"},{"key":"10.1016\/j.coph.2014.02.006_bib0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature07330","article-title":"Crystal structure of opsin in its G-protein-interacting conformation","volume":"455","author":"Scheerer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_bib0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature09789","article-title":"Crystal structure of metarhodopsin II","volume":"471","author":"Choe","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_bib0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature09648","article-title":"Structure of a nanobody-stabilized active state of the \u03b22 adrenoceptor","volume":"469","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_bib0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03b22 adrenergic receptor\u2013Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2014.02.006_bib0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/mol.111.074872","article-title":"Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects","volume":"81","author":"Valant","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coph.2014.02.006_sbref0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nature12595","article-title":"Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs","volume":"503","author":"Dror","year":"2013","journal-title":"Nature"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489214000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489214000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T13:56:23Z","timestamp":1597586183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489214000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":26,"alternative-id":["S1471489214000216"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2014.02.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}